Immunovant, Inc. (IMVT)
$
14.46
-0.10 (-0.69%)
Key metrics
Financial statements
Free cash flow per share
-2.2164
Market cap
2.5 Billion
Price to sales ratio
1.6 Thousand
Debt to equity
0.0001
Current ratio
6.0388
Income quality
0.8490
Average inventory
0
ROE
-0.7794
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Immunovant, Inc., a clinical-stage biopharmaceutical company, focuses on developing monoclonal antibodies for the treatment of autoimmune diseases. The company reported a net loss of -$259,336,000.00 indicating challenges in its operations. The total costs and expenses for the company are $282,709,000.00 reflecting its overall spending on research and development and operational activities. Additionally, the company incurred an interest expense of $0.00 which reflects its debt servicing obligations. The company reported depreciation and amortization expenses of $231,000.00 highlighting the wear and tear of its assets as it advances its clinical initiatives. Despite these challenges, the EBITDA ratio is 0.00 emphasizing the company's operational efficiency. Batoclimab, a novel fully human monoclonal antibody developed by Immunovant, selectively binds to and inhibits the neonatal fragment crystallizable receptor and is currently in Phase IIa clinical trials for treating myasthenia gravis and thyroid eye disease, with Phase II clinical trials also underway for warm autoimmune hemolytic anemia. Incorporated in 2018, Immunovant is headquartered in New York, New York, and operates as a subsidiary of Roivant Sciences Ltd. In the stock market, the company's shares are priced affordably at $14.46 making them an attractive option for budget-conscious investors. With an average trading volume of 1,740,078.00 the stock indicates moderate liquidity, allowing for potential entry and exit points for traders. The company maintains a mid-range market capitalization of $2,456,190,060.00 reflecting its status as a steady performer within its field. As a key player in the Biotechnology industry, Immunovant contributes significantly to the overall market landscape while belonging to the Healthcare sector, driving innovation and growth in the biopharmaceutical domain. This solid positioning underscores the company's commitment to advancing treatments for autoimmune diseases, and its ongoing clinical trials may pave the way for future advancements in patient care.
Is Immunovant, Inc. (IMVT) a good investment?
Investing in Immunovant, Inc. (IMVT) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bullish outlook. Always conduct your own research before investing.
What is Immunovant, Inc. (IMVT)'s stock forecast?
Analysts predict Immunovant, Inc. stock to fluctuate between $12.72 (low) and $34.47 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Immunovant, Inc.'s market capitalization?
As of 2025-05-23, Immunovant, Inc.'s market cap is $2,456,190,060, based on 169,861,000 outstanding shares.
How does Immunovant, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Immunovant, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Immunovant, Inc. (IMVT) stock?
To buy Immunovant, Inc. (IMVT) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for IMVT. Place an order (Market, Limit, etc.).
What is the best time to invest in Immunovant, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Immunovant, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$1.88 | Growth: 9.94%.
Where can I find Immunovant, Inc.'s investor relations reports?
Visit https://immunovant.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Immunovant, Inc.?
You can explore historical data from here
What is the all-time high and low for Immunovant, Inc. stock?
All-time high: $45.58 (2024-01-09) | All-time low: $3.15 (2022-06-13).
What are the key trends affecting Immunovant, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
businesswire.com
6 days ago
SAN DIEGO--(BUSINESS WIRE)--Robbins Geller Rudman & Dowd LLP announces an investigation into potential breaches of fiduciary duty by the directors and officers of Immunovant, Inc. (NASDAQ: IMVT) and Roivant Sciences Ltd. – Immunovant's controlling stockholder – in connection with Immunovant's January 2025 private placement transaction in which Roivant purchased nearly 16.9 million Immunovant shares at a price of $20.00 per share, a $3.48 per share discount to the prior trading day's closing.
globenewswire.com
a month ago
NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced next phase of growth including changes to its leadership team and the expanded development of IMVT-1402 into two new indications, SjD and CLE.
globenewswire.com
a month ago
Eric Venker, M.D. (currently President and COO of Roivant) appointed as CEO of Immunovant and Tiago Girao appointed as CFO of Immunovant Pete Salzmann, M.D.
zacks.com
2 months ago
Immunovant's batoclimab shows strong efficacy in MG & CIDP, but shifts focus to the lead drug IMVT-1402 for these indications to induce deeper, lasting relief.
seekingalpha.com
2 months ago
Immunovant, Inc. reported that positive results were achieved using batoclimab in a phase 3 study to target patients with Myasthenia Gravis; Primary endpoint met. Positive results achieved using batoclimab in phase 2b study targeting patients with Chronic Inflammatory Demyelinating Polyneuropathy; IgG was reduced by ≥ 70%. Data from both phase 3 studies, using batoclimab to treat patients with Active Thyroid Eye Disease, expected 2nd half of 2025.
prnewswire.com
2 months ago
NEW YORK , March 19, 2025 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Immunovant, Inc. (NASDAQ: IMVT) on behalf of the company's shareholders. The investigation seeks to determine whether Immunovant's directors breached their fiduciary duties in connection with recent corporate actions.
investors.com
2 months ago
Immunovant and Roivant Sciences said Wednesday their rare disease drug succeeded in a final-phase study, but the duo won't seek approval. The post Roivant, Immunovant Succeed In Phase 3.
reuters.com
2 months ago
Immunovant said on Wednesday its drug for a type of a chronic autoimmune disease that causes muscle weakness met the main goal in a late-stage trial.
globenewswire.com
2 months ago
NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported topline results from its Phase 3 study of batoclimab in MG and initial results from Period 1 of its Phase 2b study in CIDP.
globenewswire.com
2 months ago
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Wednesday, March 19th at 8:00 a.m. ET to review results from its Phase 3 study of batoclimab in MG and initial results from its Phase 2b study in CIDP.
See all news
